-+ 0.00%
-+ 0.00%
-+ 0.00%

PERSPECTIVE’S [212PB]BAMZIREOTIDE NAVOXETAN (VMT-Α-NET) DEMONSTRATES ENCOURAGING SAFETY, DURABLE DISEASE CONTROL, AND ROBUST TUMOR RESPONSE ACROSS MULTIPLE DOSE COHORTS IN PHASE 1/2A TRIAL IN ADVANCED SSTR2-EXPRESSING NETS

路透·10/23/2026 14:49:41

请登录查看新闻详情